We are live on
!
Find out more
Cardiff Oncology
CRDF
CRDF
23 hedge funds and large institutions have $1.68M invested in Cardiff Oncology in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
50% more capital invested
Capital invested by funds: $1.11M → $1.68M (+$562K)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
10% more funds holding
Funds holding: 21 → 23 (+2)
4.93% more ownership
Funds ownership: 7.39% → 12.33% (+4.9%)
Holders
23
Holders Change
+2
Holders Change %
+9.52%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$697K |
| 2 |
Renaissance Technologies
New York
|
+$285K |
| 3 |
Morgan Stanley
New York
|
+$86.5K |
| 4 |
EP
Elkhorn Partners
Omaha,
Nebraska
|
+$64.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$32.8K |
Top Sellers
| 1 |
FIA
FNY Investment Advisers
New York
|
-$7K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$6.68K |
| 3 |
PCM
Princeton Capital Management
Red Bank,
New Jersey
|
-$317 |
